Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in first-line stage IA LPHD (RIPL)
NCT00346684Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Jul 2006
- Primary completion
- Nov 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), sponsored by University of Cologne. Primary endpoint: Overall Response Rate at 4 weeks. Started Jul 2006; status: completed.
02
Drugs
rituximab
03
Conditions
nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)
Beyond the preview
Go deeper on NCT00346684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00346684.